Capivasertib
Endometrial Serous Adenocarcinoma
Explore 12 assets in Endometrial Serous Adenocarcinoma →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03660826CT.gov Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Endometrial Serous Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Capivasertib (this asset) | National Cancer Institute (NCI) | P2 | CCC · 53 |
| Carboplatin | National Cancer Institute (NCI) | P3 | BB |
| Temsirolimus | National Cancer Institute (NCI) | P2 | B |
| Cediranib | National Cancer Institute (NCI) | P2 | B |
| Cabozantinib | National Cancer Institute (NCI) | P2 | B |
| Pembrolizumab | Roswell Park Cancer Institute | P2 | CCC |
| Doxycycline | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | P2 | CCC |
| Olaparib | National Cancer Institute (NCI) | P2 | CCC |
| Durvalumab | National Cancer Institute (NCI) | P2 | CCC |
+14 more in the Endometrial Serous Adenocarcinoma cohort
Other indications for Capivasertib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Triple-Negative Breast Carcinoma | — | P3 | BB · 71 |
| Estrogen-Receptor Positive Breast Cancer | — | P2 | BB · 70 |
| Castration-Resistant Prostate Carcinoma | — | P3 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Capivasertib in Endometrial Serous Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/capivasertib-endometrial-serous-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →